Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006046 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00006046 is a Phase 1 study that was terminated before completion, run by Ludwig Institute for Cancer Research. The registered enrollment target is 7 participants.
The verdict
NCT00006046, a Phase 1 study, was terminated before completion, sponsored by Ludwig Institute for Cancer Research.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have advanced colorectal cancer.
Interventions
- BIOLOGICAL monoclonal antibody hu3S193
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2000-07-12 |
| Est. Completion | 2002-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006046
The ClinicalTrials.gov registry entry for NCT00006046 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody hu3S193 is the first listed.
NCT00006046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006046 about?
NCT00006046 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have advanced colorectal cancer.
What is the current status of trial NCT00006046?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2000-07-12. Estimated completion is 2002-09-24.
What interventions are being tested in trial NCT00006046?
The interventions under investigation include: monoclonal antibody hu3S193 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006046?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.